Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06177366
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-20
First Post:
2023-12-11
Brief Title:
A New Blood Score for Myelofibrosis Staging
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Development of a Blood Score for Myelofibrosis Staging in BCRABL1 Negative Myeloproliferative Neoplasms Using Bone Marrow Biopsy as a Gold Standard
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FIBROMOELLE
Brief Summary:
BCRABL1 negative myeloproliferative neoplasms MPN include three entities polycythemia vera essential thrombocythemia and primitive myelofibrosis Myelofibrosis is a life-threatening complication in MPN with several therapeutic options including hematopoietic stem cell transplantation HSCT which remains the only curative treatment Bone marrow biopsy with histological analysis allows myelofibrosis identification and staging However it is an invasive procedure that remains painful and provides potential haemorrhagic complications Development of non-invasive biomarkers for myelofibrosis staging could help to better stratify this disease better define patients prognosis and lead to optimal cares
The main aim of this work is to develop a non-invasive blood score including several biomarkers for myelofibrosis staging in MPN using bone marrow biopsy as a gold standard
The main aim of this work is to develop a non-invasive blood score including several biomarkers for myelofibrosis staging in MPN using bone marrow biopsy as a gold standard
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None